All the sessions from Transform 2021 are available on-demand now. Watch now.

ALPHARETTA, Ga.–(BUSINESS WIRE)–February 29, 2016–

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced that Richard J. Croarkin has been appointed to Clearside’s Board of Directors. Mr. Croarkin is the former Senior Vice President of Finance, Chief Financial Officer & Corporate Strategy Officer of Alcon, Inc. and brings extensive global financial experience from working for diverse companies, including Nestlé Health Science S.A., Pepsico Incorporated and AMAX, Inc.

“We are delighted to have Rick join our Board of Directors,” said Daniel H. White, CEO and President of Clearside. “Rick’s extensive financial experience and understanding of the medical industry will be invaluable to Clearside as our company continues to grow.”

“I am excited about the opportunity to work with the team at Clearside as they advance the treatment of blinding diseases of the back-of-the-eye using their proprietary suprachoroidal space (SCS™) microinjector-based drug therapies delivered via the suprachoroidal space,” said Mr. Croarkin.

Mr. Croarkin served as Chief Financial Officer of Nestlé Health Science S.A., a division of Nestlé focused on medicalized nutrition solutions for chronic medical conditions. As noted above, Mr. Croarkin worked at Alcon, Inc. from August 2007 to November 2010. Prior to Alcon, he served as Executive Vice President and Chief Financial Officer of Nestlé Waters North America. Before joining Nestlé, Mr. Croarkin worked for Pepsico Incorporated for 11 years where he served in several global senior financial positions including Chief Financial Officer of Pepsi-Cola Latin America and Pepsi-Cola Canada. Mr. Croarkin started his career with AMAX, Inc. where he worked in treasury, corporate development and planning. He holds a BA in Economics from Georgetown University, an MBA in Finance from the University of Connecticut and a Diploma in French language from Alliance Francaise in Paris, France.

Mr. Croarkin is currently a Director on the Board of Aerie Pharmaceuticals, Inc., which he joined in May 2015. Mr. Croarkin also serves as a panelist on the NASDAQ Listing Qualifications Panel.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary SCS™ microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye.

Clearside Biomedical, Inc.
Charles Deignan, 678-270-4005
Chief Financial Officer
The Trout Group
Matthew Beck, 646-378-2933


VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member